Publicacións (152) Publicacións nas que participase algún/ha investigador/a

2024

  1. Biodistribution and pharmacokinetics of [89Zr]-anti-VEGF mAbs using PET in glioblastoma rat models

    International Journal of Pharmaceutics, Vol. 652

  2. EANM perspectives for CZT SPECT in brain applications

    European Journal of Nuclear Medicine and Molecular Imaging

  3. Neuroimaging biomarkers in the biological definition of Parkinson’s disease and dementia with Lewy bodies – EANM position on current state, unmet needs and future perspectives

    European Journal of Nuclear Medicine and Molecular Imaging

  4. Partial volume correction in longitudinal tau PET studies: is it really needed?

    NeuroImage, Vol. 289

  5. Perspectives of the European Association of Nuclear Medicine on the role of artificial intelligence (AI) in molecular brain imaging

    European Journal of Nuclear Medicine and Molecular Imaging

2023

  1. A murine model of BSCL2-associated Celia's encephalopathy

    Neurobiology of Disease, Vol. 187

  2. Association of periodontitis with cognitive decline and its progression: Contribution of blood-based biomarkers of Alzheimer's disease to this relationship

    Journal of Clinical Periodontology, Vol. 50, Núm. 11, pp. 1444-1454

  3. Description of a different quantification method for amyloid burden (burdenDPD) and validation of SPECT/CT in cardiac amyloidosis

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 3, pp. 171-177

  4. EANM position paper: theranostics in brain tumours—the present and the future

    European Journal of Nuclear Medicine and Molecular Imaging

  5. FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective

    European Journal of Nuclear Medicine and Molecular Imaging

  6. First experimental measurements of 2D microdosimetry maps in proton therapy

    Medical Physics, Vol. 50, Núm. 1, pp. 570-581

  7. Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity

    JAMA neurology

  8. Pharmacokinetic Evaluation of New Drugs Using a Multi-Labelling Approach and PET Imaging: Application to a Drug Candidate with Potential Application in Neuromuscular Disorders

    Biomedicines, Vol. 11, Núm. 2

  9. Prevalencia de dislipemia aterogénica, factores relacionados y grado de control lipídico en la población general de Galicia: Estudio GALIPEMIAS

    Clínica e investigación en arteriosclerosis, Vol. 35, Núm. 4, pp. 178-184

  10. Quantitative PET tracking of intra-articularly administered 89Zr-peptide-decorated nanoemulsions

    Journal of Controlled Release, Vol. 356, pp. 702-713

  11. Role of systemic inflammatory factors in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with peptide receptor radionuclide therapy (PRRT): From biology to theragnosis

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 3, pp. 156-162

2022

  1. 18F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Núm. 4, pp. 1242-1253

  2. Charge collection efficiency, underlying recombination mechanisms, and the role of electrode distance of vented ionization chambers under ultra-high dose-per-pulse conditions

    Physica Medica, Vol. 104, pp. 10-17

  3. Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence

    Pharmaceutics, Vol. 14, Núm. 10

  4. Development of Improved Dosimetry Standards for FLASH Radiotherapy: The UHDpulse Project

    Proceedings of the 14th International Conference on Radiation Shielding and 21st Topical Meeting of the Radiation Protection and Shielding Division, ICRS 2022/RPSD 2022